Reaffirming its bold ambition to become the leading dermatology company in the world, Swiss pharmaceutical company Galderma has announced its intention to expand its manufacturing and innovation footprint in the Asia-Pacific region, with support from the Singapore Economic Development Board.

Galderma intends to explore opportunities to build a fifth manufacturing plant with a high degree of digitalization and automation in Singapore in response to growing consumer demand and to support long-term sustainable growth over the coming years.

The announcement comes as part of Galderma's strategic manufacturing roadmap, aligned with the company's unique Integrated Dermatology Strategy.

Following a record 2021 performance, Galderma has demonstrated strong commercial and financial performance in the first half of 2022, with continued strong growth across product categories. In particular, Dermo-cosmetics has grown by 31% year‑on‑year on a constant currency basis, fueled by the strong performance of Cetaphil driven by e‑commerce and launches in China and the rest of Asia.